Global Next Generation Antibody Therapeutics Market

Next Generation Antibody Therapeutics Comprehensive Study by Type (Antibody Drug Conjugates (ADCs), Bispecific Antibodies (BsAbs), Fc Engineered Antibodies, Antibody Fragments and Antibody-Like Proteins (AF & ALPs), Biosimilar Antibody (Ab) Products), Application (Oncology, Autoimmune/Inflammatory), End User (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2024

Next Generation Antibody Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
A multitude of innovative therapeutic antibody formats based on modification of the conventional IgG format have arisen in recent years. The increase of interest in this area reflects a pressing need for an additional repertoire of therapeutic molecules which retain the exquisite binding specificity and low intrinsic toxicity of monoclonal antibodies (mAbs), whereas engineering additional features which enhance clinical efficacy, for instance, by improving tissue perfusion or demonstrating increased specificity for a defined cell type.This growth is primarily driven by Rising Number of Collaborations for R&D in Next-Generation Antibody Therapeutics and Increasing Prevalence of Chronic Diseases.

Globally, a noticeable market trend is evident Growing Popularity of ADC Technology. Major Players, such as ImmunoGen, Inc. (United States), Bayer AG (Germany), Biogen (United States), Xencor, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Kyowa Hakko Kirin Co., Ltd. (Japan), Dyax Corp. (United States), Seattle Genetics, Inc. (United States), Pfizer (United States) and Bristol-Myers Squibb (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On 28 March, 2019 - AstraZeneca has entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment.

Market Drivers
  • Rising Number of Collaborations for R&D in Next-Generation Antibody Therapeutics
  • Increasing Prevalence of Chronic Diseases

Market Trend
  • Growing Popularity of ADC Technology

Restraints
  • Higher Costs of Therapeutics

Opportunities
Technological Advancements in Antibody Therapeutics
Challenges
Stringent Regulatory Related to Antibody Therapeutics and Lengthy Approval Processes

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • Antibody Drug Conjugates (ADCs)
  • Bispecific Antibodies (BsAbs)
  • Fc Engineered Antibodies
  • Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
  • Biosimilar Antibody (Ab) Products
By Application
  • Oncology
  • Autoimmune/Inflammatory
By End User
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of Collaborations for R&D in Next-Generation Antibody Therapeutics
      • 3.2.2. Increasing Prevalence of Chronic Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Related to Antibody Therapeutics
      • 3.3.2. Lengthy Approval Processes
    • 3.4. Market Trends
      • 3.4.1. Growing Popularity of ADC Technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Next Generation Antibody Therapeutics, by Type, Application, End User and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Next Generation Antibody Therapeutics (Value)
      • 5.2.1. Global Next Generation Antibody Therapeutics by: Type (Value)
        • 5.2.1.1. Antibody Drug Conjugates (ADCs)
        • 5.2.1.2. Bispecific Antibodies (BsAbs)
        • 5.2.1.3. Fc Engineered Antibodies
        • 5.2.1.4. Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
        • 5.2.1.5. Biosimilar Antibody (Ab) Products
      • 5.2.2. Global Next Generation Antibody Therapeutics by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Autoimmune/Inflammatory
      • 5.2.3. Global Next Generation Antibody Therapeutics by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Next Generation Antibody Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Next Generation Antibody Therapeutics (Price)
      • 5.3.1. Global Next Generation Antibody Therapeutics by: Type (Price)
  • 6. Next Generation Antibody Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ImmunoGen, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biogen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Xencor, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kyowa Hakko Kirin Co., Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dyax Corp. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Seattle Genetics, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Next Generation Antibody Therapeutics Sale, by Type, Application, End User and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Next Generation Antibody Therapeutics (Value)
      • 7.2.1. Global Next Generation Antibody Therapeutics by: Type (Value)
        • 7.2.1.1. Antibody Drug Conjugates (ADCs)
        • 7.2.1.2. Bispecific Antibodies (BsAbs)
        • 7.2.1.3. Fc Engineered Antibodies
        • 7.2.1.4. Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
        • 7.2.1.5. Biosimilar Antibody (Ab) Products
      • 7.2.2. Global Next Generation Antibody Therapeutics by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Autoimmune/Inflammatory
      • 7.2.3. Global Next Generation Antibody Therapeutics by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Next Generation Antibody Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Next Generation Antibody Therapeutics (Price)
      • 7.3.1. Global Next Generation Antibody Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Next Generation Antibody Therapeutics: by Type(USD Million)
  • Table 2. Next Generation Antibody Therapeutics Antibody Drug Conjugates (ADCs) , by Region USD Million (2013-2018)
  • Table 3. Next Generation Antibody Therapeutics Bispecific Antibodies (BsAbs) , by Region USD Million (2013-2018)
  • Table 4. Next Generation Antibody Therapeutics Fc Engineered Antibodies , by Region USD Million (2013-2018)
  • Table 5. Next Generation Antibody Therapeutics Antibody Fragments and Antibody-Like Proteins (AF & ALPs) , by Region USD Million (2013-2018)
  • Table 6. Next Generation Antibody Therapeutics Biosimilar Antibody (Ab) Products , by Region USD Million (2013-2018)
  • Table 7. Next Generation Antibody Therapeutics: by Application(USD Million)
  • Table 8. Next Generation Antibody Therapeutics Oncology , by Region USD Million (2013-2018)
  • Table 9. Next Generation Antibody Therapeutics Autoimmune/Inflammatory , by Region USD Million (2013-2018)
  • Table 10. Next Generation Antibody Therapeutics: by End User(USD Million)
  • Table 11. Next Generation Antibody Therapeutics Hospitals , by Region USD Million (2013-2018)
  • Table 12. Next Generation Antibody Therapeutics Clinics , by Region USD Million (2013-2018)
  • Table 13. Next Generation Antibody Therapeutics Others , by Region USD Million (2013-2018)
  • Table 14. South America Next Generation Antibody Therapeutics, by Country USD Million (2013-2018)
  • Table 15. South America Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 16. South America Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 17. South America Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 18. Brazil Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 19. Brazil Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 20. Brazil Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 21. Argentina Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 22. Argentina Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 23. Argentina Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 24. Rest of South America Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 25. Rest of South America Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 26. Rest of South America Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 27. Asia Pacific Next Generation Antibody Therapeutics, by Country USD Million (2013-2018)
  • Table 28. Asia Pacific Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 29. Asia Pacific Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 30. Asia Pacific Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 31. China Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 32. China Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 33. China Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 34. Japan Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 35. Japan Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 36. Japan Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 37. India Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 38. India Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 39. India Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 40. South Korea Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 41. South Korea Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 42. South Korea Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 43. Taiwan Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 44. Taiwan Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 45. Taiwan Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 46. Australia Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 47. Australia Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 48. Australia Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 49. Rest of Asia-Pacific Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 52. Europe Next Generation Antibody Therapeutics, by Country USD Million (2013-2018)
  • Table 53. Europe Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 54. Europe Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 55. Europe Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 56. Germany Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 57. Germany Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 58. Germany Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 59. France Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 60. France Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 61. France Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 62. Italy Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 63. Italy Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 64. Italy Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 65. United Kingdom Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 66. United Kingdom Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 67. United Kingdom Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 68. Netherlands Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 69. Netherlands Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 70. Netherlands Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 71. Rest of Europe Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 72. Rest of Europe Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 73. Rest of Europe Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 74. MEA Next Generation Antibody Therapeutics, by Country USD Million (2013-2018)
  • Table 75. MEA Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 76. MEA Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 77. MEA Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 78. Middle East Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 79. Middle East Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 80. Middle East Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 81. Africa Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 82. Africa Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 83. Africa Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 84. North America Next Generation Antibody Therapeutics, by Country USD Million (2013-2018)
  • Table 85. North America Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 86. North America Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 87. North America Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 88. United States Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 89. United States Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 90. United States Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 91. Canada Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 92. Canada Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 93. Canada Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 94. Mexico Next Generation Antibody Therapeutics, by Type USD Million (2013-2018)
  • Table 95. Mexico Next Generation Antibody Therapeutics, by Application USD Million (2013-2018)
  • Table 96. Mexico Next Generation Antibody Therapeutics, by End User USD Million (2013-2018)
  • Table 97. Next Generation Antibody Therapeutics: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Next Generation Antibody Therapeutics: by Type(USD Million)
  • Table 109. Next Generation Antibody Therapeutics Antibody Drug Conjugates (ADCs) , by Region USD Million (2019-2024)
  • Table 110. Next Generation Antibody Therapeutics Bispecific Antibodies (BsAbs) , by Region USD Million (2019-2024)
  • Table 111. Next Generation Antibody Therapeutics Fc Engineered Antibodies , by Region USD Million (2019-2024)
  • Table 112. Next Generation Antibody Therapeutics Antibody Fragments and Antibody-Like Proteins (AF & ALPs) , by Region USD Million (2019-2024)
  • Table 113. Next Generation Antibody Therapeutics Biosimilar Antibody (Ab) Products , by Region USD Million (2019-2024)
  • Table 114. Next Generation Antibody Therapeutics: by Application(USD Million)
  • Table 115. Next Generation Antibody Therapeutics Oncology , by Region USD Million (2019-2024)
  • Table 116. Next Generation Antibody Therapeutics Autoimmune/Inflammatory , by Region USD Million (2019-2024)
  • Table 117. Next Generation Antibody Therapeutics: by End User(USD Million)
  • Table 118. Next Generation Antibody Therapeutics Hospitals , by Region USD Million (2019-2024)
  • Table 119. Next Generation Antibody Therapeutics Clinics , by Region USD Million (2019-2024)
  • Table 120. Next Generation Antibody Therapeutics Others , by Region USD Million (2019-2024)
  • Table 121. South America Next Generation Antibody Therapeutics, by Country USD Million (2019-2024)
  • Table 122. South America Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 123. South America Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 124. South America Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 125. Brazil Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 126. Brazil Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 127. Brazil Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 128. Argentina Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 129. Argentina Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 130. Argentina Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 131. Rest of South America Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 132. Rest of South America Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 133. Rest of South America Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 134. Asia Pacific Next Generation Antibody Therapeutics, by Country USD Million (2019-2024)
  • Table 135. Asia Pacific Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 136. Asia Pacific Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 137. Asia Pacific Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 138. China Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 139. China Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 140. China Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 141. Japan Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 142. Japan Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 143. Japan Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 144. India Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 145. India Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 146. India Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 147. South Korea Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 148. South Korea Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 149. South Korea Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 150. Taiwan Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 151. Taiwan Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 152. Taiwan Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 153. Australia Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 154. Australia Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 155. Australia Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 156. Rest of Asia-Pacific Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 157. Rest of Asia-Pacific Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 158. Rest of Asia-Pacific Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 159. Europe Next Generation Antibody Therapeutics, by Country USD Million (2019-2024)
  • Table 160. Europe Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 161. Europe Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 162. Europe Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 163. Germany Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 164. Germany Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 165. Germany Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 166. France Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 167. France Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 168. France Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 169. Italy Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 170. Italy Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 171. Italy Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 172. United Kingdom Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 173. United Kingdom Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 174. United Kingdom Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 175. Netherlands Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 176. Netherlands Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 177. Netherlands Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 178. Rest of Europe Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 179. Rest of Europe Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 180. Rest of Europe Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 181. MEA Next Generation Antibody Therapeutics, by Country USD Million (2019-2024)
  • Table 182. MEA Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 183. MEA Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 184. MEA Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 185. Middle East Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 186. Middle East Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 187. Middle East Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 188. Africa Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 189. Africa Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 190. Africa Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 191. North America Next Generation Antibody Therapeutics, by Country USD Million (2019-2024)
  • Table 192. North America Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 193. North America Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 194. North America Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 195. United States Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 196. United States Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 197. United States Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 198. Canada Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 199. Canada Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 200. Canada Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 201. Mexico Next Generation Antibody Therapeutics, by Type USD Million (2019-2024)
  • Table 202. Mexico Next Generation Antibody Therapeutics, by Application USD Million (2019-2024)
  • Table 203. Mexico Next Generation Antibody Therapeutics, by End User USD Million (2019-2024)
  • Table 204. Next Generation Antibody Therapeutics: by Type(USD/Units)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Next Generation Antibody Therapeutics: by Type USD Million (2013-2018)
  • Figure 5. Global Next Generation Antibody Therapeutics: by Application USD Million (2013-2018)
  • Figure 6. Global Next Generation Antibody Therapeutics: by End User USD Million (2013-2018)
  • Figure 7. South America Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 9. Europe Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 10. MEA Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 11. North America Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 12. Global Next Generation Antibody Therapeutics: by Type USD/Units (2013-2018)
  • Figure 13. Global Next Generation Antibody Therapeutics share by Players 2018 (%)
  • Figure 14. Global Next Generation Antibody Therapeutics share by Players (Top 3) 2018(%)
  • Figure 15. Global Next Generation Antibody Therapeutics share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. ImmunoGen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. ImmunoGen, Inc. (United States) Revenue: by Geography 2018
  • Figure 19. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer AG (Germany) Revenue: by Geography 2018
  • Figure 21. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 22. Biogen (United States) Revenue: by Geography 2018
  • Figure 23. Xencor, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Xencor, Inc. (United States) Revenue: by Geography 2018
  • Figure 25. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2018
  • Figure 27. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Kyowa Hakko Kirin Co., Ltd. (Japan) Revenue: by Geography 2018
  • Figure 29. Dyax Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Dyax Corp. (United States) Revenue: by Geography 2018
  • Figure 31. Seattle Genetics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Seattle Genetics, Inc. (United States) Revenue: by Geography 2018
  • Figure 33. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer (United States) Revenue: by Geography 2018
  • Figure 35. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bristol-Myers Squibb (United States) Revenue: by Geography 2018
  • Figure 37. Global Next Generation Antibody Therapeutics: by Type USD Million (2019-2024)
  • Figure 38. Global Next Generation Antibody Therapeutics: by Application USD Million (2019-2024)
  • Figure 39. Global Next Generation Antibody Therapeutics: by End User USD Million (2019-2024)
  • Figure 40. South America Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 41. Asia Pacific Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 42. Europe Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 43. MEA Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 44. North America Next Generation Antibody Therapeutics Share (%), by Country
  • Figure 45. Global Next Generation Antibody Therapeutics: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • ImmunoGen, Inc. (United States)
  • Bayer AG (Germany)
  • Biogen (United States)
  • Xencor, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Kyowa Hakko Kirin Co., Ltd. (Japan)
  • Dyax Corp. (United States)
  • Seattle Genetics, Inc. (United States)
  • Pfizer (United States)
  • Bristol-Myers Squibb (United States)
Additional players considered in the study are as follows:
AstraZeneca (United Kingdom) , Amgen, Inc. (United States)
Select User Access Type

Key Highlights of Report


May 2019 225 Pages 73 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Next Generation Antibody Therapeutics Market Quantitative research analysis
Global Next Generation Antibody Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Next Generation Antibody Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Microsclerotherapy Treatment Comprehensive Study by Type (Sclerosants (Chromated Glycerin, Sodium Tetradecyl Sulfate, Polidocanol, Others), Micro-Needles, Graduated Compression Hosiery Supports, Othe...
$ 3450
Halitosis Treatment Comprehensive Study by Type (Pathological, Non-pathological), Application (Lungs, Liver, Respiratory, Systemic, Gastrointestinal, Others), Diagnostic Tests (Gas chromatography, Ha...
$ 3750
Circulating Tumor Cells (CTC) Comprehensive Study by Type (Ex-Vivo Positive Selection, In-Vivo Positive Selection, Negative Selection, Microchips & Single Spiral Micro Channel), Application (Tumorige...
$ 3450
Sleep Disorder Therapeutics Comprehensive Study by Type (Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, Others), Medical Devices) Players and ...
$ 3500
Shingles Treatments Comprehensive Study by Type (Antiviral Medications, Narcotic Medications, Anti-Inflammatory Medications, Antihistamines, Anticonvulsants, Creams, Others), Route of Administration ...
$ 3450
Schizophrenia Treatments Comprehensive Study by Type (Medications, Conventional or Typical Antipsychotic Drugs, Atypical Antipsychotic Drugs, Therapies), End Users (Hospital Pharmacies, Drug Stores, ...
$ 3650